BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 20682692)

  • 1. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy.
    Li J; Qu X; Yao J; Caruana G; Ricardo SD; Yamamoto Y; Yamamoto H; Bertram JF
    Diabetes; 2010 Oct; 59(10):2612-24. PubMed ID: 20682692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice.
    Li J; Qu X; Bertram JF
    Am J Pathol; 2009 Oct; 175(4):1380-8. PubMed ID: 19729486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α2-antiplasmin positively regulates endothelial-to-mesenchymal transition and fibrosis progression in diabetic nephropathy.
    Kanno Y; Hirota M; Matsuo O; Ozaki KI
    Mol Biol Rep; 2022 Jan; 49(1):205-215. PubMed ID: 34709571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FSP1-specific SMAD2 knockout in renal tubular, endothelial, and interstitial cells reduces fibrosis and epithelial-to-mesenchymal transition in murine STZ-induced diabetic nephropathy.
    Loeffler I; Liebisch M; Allert S; Kunisch E; Kinne RW; Wolf G
    Cell Tissue Res; 2018 Apr; 372(1):115-133. PubMed ID: 29209813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
    Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
    Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy.
    Ding D; Du Y; Qiu Z; Yan S; Chen F; Wang M; Yang S; Zhou Y; Hu X; Deng Y; Wang S; Wang L; Zhang H; Wu H; Yu X; Zhou Z; Liao Y; Chen X
    J Mol Med (Berl); 2016 Feb; 94(2):207-18. PubMed ID: 26407577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review: Endothelial-myofibroblast transition, a new player in diabetic renal fibrosis.
    Li J; Bertram JF
    Nephrology (Carlton); 2010 Aug; 15(5):507-12. PubMed ID: 20649869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loganin attenuates diabetic nephropathy in C57BL/6J mice with diabetes induced by streptozotocin and fed with diets containing high level of advanced glycation end products.
    Liu K; Xu H; Lv G; Liu B; Lee MK; Lu C; Lv X; Wu Y
    Life Sci; 2015 Feb; 123():78-85. PubMed ID: 25623853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate attenuates diabetic nephropathy in experimental diabetic rat's model via suppression of augmented TGF-β1/Smad3 signaling pathway.
    Al-Rasheed NM; Al-Rasheed NM; Al-Amin MA; Hasan IH; Al-Ajmi HN; Mohammad RA; Attia HA
    Arch Physiol Biochem; 2016 Oct; 122(4):186-194. PubMed ID: 26959841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model.
    Wang XX; Jiang T; Shen Y; Caldas Y; Miyazaki-Anzai S; Santamaria H; Urbanek C; Solis N; Scherzer P; Lewis L; Gonzalez FJ; Adorini L; Pruzanski M; Kopp JB; Verlander JW; Levi M
    Diabetes; 2010 Nov; 59(11):2916-27. PubMed ID: 20699418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C3a receptor antagonist ameliorates inflammatory and fibrotic signals in type 2 diabetic nephropathy by suppressing the activation of TGF-β/smad3 and IKBα pathway.
    Li L; Yin Q; Tang X; Bai L; Zhang J; Gou S; Zhu H; Cheng J; Fu P; Liu F
    PLoS One; 2014; 9(11):e113639. PubMed ID: 25422985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of type VIII collagen in mice ameliorates diabetic nephropathy.
    Hopfer U; Hopfer H; Meyer-Schwesinger C; Loeffler I; Fukai N; Olsen BR; Stahl RA; Wolf G
    Diabetes; 2009 Jul; 58(7):1672-81. PubMed ID: 19401424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria.
    Wang A; Ziyadeh FN; Lee EY; Pyagay PE; Sung SH; Sheardown SA; Laping NJ; Chen S
    Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1657-65. PubMed ID: 17804483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FPS-ZM1 and valsartan combination protects better against glomerular filtration barrier damage in streptozotocin-induced diabetic rats.
    Sanajou D; Ghorbani Haghjo A; Argani H; Roshangar L; Ahmad SNS; Jigheh ZA; Aslani S; Panah F; Rashedi J; Mesgari Abbasi M
    J Physiol Biochem; 2018 Aug; 74(3):467-478. PubMed ID: 29948786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy.
    Kobayashi S; Satoh M; Namikoshi T; Haruna Y; Fujimoto S; Arakawa S; Komai N; Tomita N; Sasaki T; Kashihara N
    Clin Exp Nephrol; 2008 Apr; 12(2):119-125. PubMed ID: 18175064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion of Smad3 prevents renal fibrosis and inflammation in type 2 diabetic nephropathy.
    Xu BH; Sheng J; You YK; Huang XR; Ma RCW; Wang Q; Lan HY
    Metabolism; 2020 Feb; 103():154013. PubMed ID: 31734275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling.
    Chung AC; Zhang H; Kong YZ; Tan JJ; Huang XR; Kopp JB; Lan HY
    J Am Soc Nephrol; 2010 Feb; 21(2):249-60. PubMed ID: 19959709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats.
    Lu L; Peng WH; Wang W; Wang LJ; Chen QJ; Shen WF
    J Zhejiang Univ Sci B; 2011 Aug; 12(8):652-9. PubMed ID: 21796806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway.
    Thallas-Bonke V; Thorpe SR; Coughlan MT; Fukami K; Yap FY; Sourris KC; Penfold SA; Bach LA; Cooper ME; Forbes JM
    Diabetes; 2008 Feb; 57(2):460-9. PubMed ID: 17959934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN).
    Yuan Y; Sun H; Sun Z
    Lipids Health Dis; 2017 Jun; 16(1):126. PubMed ID: 28659153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.